MB-272 is under clinical development by MiroBio and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MB-272’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MB-272 is under development for the treatment of autoimmune diseases. It acts by targeting B and T lymphocyte attenuator (BTLA).
MiroBio, is a biotherapeutics company that develops immune-modulatory therapies and regulation of receptor signalling in immune cells. The company is headquartered in United Kingdom.
For a complete picture of MB-272’s drug-specific PTSR and LoA scores, buy the report here.